Patent · US Active

Anti-PD-L1 antibodies and uses thereof

US10208119B2 · kind B2 · utility

9Cited by

1References

18Claims

0Family size

Assignee

I-MAB · KY

Inventors

Lei Fang · Katy, US
Zhengyi Wang · Shanghai, CN
Bingshi Guo · Shanghai, CN
Jingwu Zang · Shanghai, CN

Key dates

Filing date	Aug 9, 2018
Grant date	Feb 19, 2019
Priority date	—
Expiry date	Aug 9, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.